Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA RECALLS & COURT ACTIONS: June 16, 1993

Executive Summary

CLASS II - PERITRATE SA (PENTAERYTHRITOL TETRANITRATE) SUSTAINED ACTION TABLETS In bottles of 100, indicated for the relief of angina pectoris. Recall number: D-278-3. All lots within expiration date. Manufacturer: Warner Lambert, Inc., Vega Baja, Puerto Rico. Recalled by: Parke-Davis, Division of Warner Lambert Company, Morris Plain, New Jersey, by letter on or about June 1, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 253,550 units were distributed. Reason: Dissolution specification not assured through expiration date. CLASS III - EQUAGESIC TABLETS (MEPROBAMATE WITH ASPIRIN) In bottles of 100, used for the treatment of pain in patients with musculoskeletal disease. Recall number: D-275-3. Lot number 9920691. Manufacturer: Wyeth-Ayerst Laboratories, St. Davids, Pennsylvania. Recalled by: Manufacturer, by letter May 24, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 6,978 bottles were distributed. Reason: Some tablets contain only the meprobamate component. CLASS III - LIDOCAINE HCL ORAL TOPICAL SOLUTION, USP, 2% (VISCOUS) An Rx topical anesthesia for use on irritated mucous membranes of the mouth and pharynx, in 20 ml (PBI label only) and 100 ml bottles under the following labels: PBI, GG (Geneva), Goldline, Rugby, Qualitest, Major. Recall number: D-277-3. Lot number 19165 EXP 10/31/94 (100 ml) and 10/31/93 (20 ml). Manufacturer: Pharmaceutical Basics, Inc., Morton Grove, Illinois. Recalled by: Pennex Pharmaceuticals, Inc., Morton Grove, Illinois, by letter June 4, 1993. Firm-initiated recall ongoing. Distribution: Nationwide; 3,392 20-ml bottles and 86,979 100-ml bottles were distributed. Reason: Superpotent. CLASS III - MALLINCKRODT MEDICAL TECHNESCAN DTPA KIT For the preparation of Technetium TC 99m Penetate, packaged in 5 vial kits and 30 vial kits. Recall number: D-274-3. Lot number 2272 EXP 8/95. Manufacturer: CIS-US, Inc., Bedford, Massachusetts. Recalled by: Manufacturer, by letters of May 11 and 14, 1993. Firm- initiated recall ongoing. Distribution: Nationwide, Panama, Mexico, Jamaica, Phillipines; 402 5-packs and 254 30-packs were distributed. Reason: Expiration date is August 1994 instead of declared August 1995. SEIZURE - PROSTAZINC TABLETS (93-556-601) Charges: New drug -- The article is an unapproved new drug. Misbranded -- The article's labeling is false and misleading, fails to contain all required words, statements, and other information, and fails to bear adequate directions for use. Firm: Food Health Services & Ideas, Miami, Florida. Filed: March 23, 1993; U.S. District Court for the Southern District of Florida; Civil number 93-0521-CIV-ATKINS; FDA number 66656. Seized: March 24, 1993 - goods valued at approximately $50,000.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS022812

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel